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SHORT COMMUNICATION
Crosstalk between NRF2 and HIPK2 shapes cytoprotective
responses
L Torrente1, C Sanchez1, R Moreno1, S Chowdhry1, P Cabello1, K Isono2, H Koseki2, T Honda3, JD Hayes1, AT Dinkova-Kostova1 and
L de la Vega1
Homeodomain interacting protein kinase-2 (HIPK2) is a member of the HIPK family of stress-responsive kinases that modulates cell
growth, apoptosis, proliferation and development. HIPK2 has several well-characterised tumour suppressor roles, but recent studies
suggest it can also contribute to tumour progression, although the underlying mechanisms are unknown. Herein, we have
identiﬁed novel crosstalk between HIPK2 and the cytoprotective transcription factor NRF2. We show that HIPK2 is a direct
transcriptional target of NRF2, identifying a functional NRF2 binding site in the HIPK2 gene locus and demonstrating for the ﬁrst
time a transcriptional mode of regulation for this kinase. In addition, HIPK2 is required for robust NRF2 responsiveness in cells and
in vivo. By using both gain-of-function and loss-of-function approaches, we demonstrate that HIPK2 can elicit a cytoprotective
response in cancer cells via NRF2. Our results have uncovered a new downstream effector of HIPK2, NRF2, which is frequently
activated in human tumours correlating with chemoresistance and poor prognosis. Furthermore, our results suggest that
modulation of either HIPK2 levels or activity could be exploited to impair NRF2-mediated signalling in cancer cells, and thus
sensitise them to chemotherapeutic drugs.
Oncogene advance online publication, 10 July 2017; doi:10.1038/onc.2017.221
INTRODUCTION
Homeodomain interacting protein kinase-2 (HIPK2) is a member of
the HIPK family of stress-responsive kinases, and it modulates cell
proliferation, differentiation, apoptosis and development.1–7 HIPK2
responds to a variety of physiological stresses,3,8–12 transforming
these cues into changes in transcriptional programs, which in turn
enables cells to adapt to and survive the original insult. Although
HIPK2 is highly regulated at the posttranslational level,9,10,13–20
essentially no information exists about its transcriptional regulation.
HIPK2 is considered to be a potential haplo-insufﬁcient tumour
suppressor as it can promote apoptosis in response to
chemotherapeutic drugs and radiation, mainly by phosphorylating
p53 at S46,1,21 which then induces expression of pro-apoptotic
genes. Additionally, HIPK2 can also protect cells against genome
instability induced by genotoxic agents by promoting DNA
damage repair pathways.17,22 Interestingly, accumulating evidence
suggests that HIPK2 may also support tumour progression: the
expression of HIPK2 is signiﬁcantly higher in cervical cancer than
in healthy tissue23 and in aggressive meningiomas (when
compared with benign meningiomas), where it positively associ-
ates with tumour progression.24 HIPK2 is also ampliﬁed in pilocytic
astrocytoma25 and in ovarian and prostate tumours (The Cancer
Genome Atlas), and positively associates with cell growth in
various cancer cell lines.25–27 These results imply that HIPK2 might
play a dual role in cancer depending on context, either acting as a
tumour suppressor or facilitating tumour progression. While the
pathways involved in the tumour suppressor role of HIPK2 are
relatively well understood, the underlying mechanisms mediating
its cytoprotective function(s) remain unclear.
NRF2 (nuclear factor erythroid 2 (NF-E2) p45-related factor 2,
encoded by NFE2L2) is the master regulator of oxidative stress
responses, which allows adaptation and survival during stress
conditions. NRF2 controls the expression of a battery of genes,
which encode antioxidant and drug-metabolising enzymes, as
well as drug transporters (for example, HO1, GSTs, NQO1 and
MRPs), all of which contain antioxidant response elements (AREs)
within their promoter/enhancer regions.28,29 In normal cells, NRF2
activity is kept low under non-stress conditions by its rapid
proteasomal degradation, which is principally mediated by KEAP1
(a substrate adaptor for a Cul3-based E3 ubiquitin ligase).30,31
Upon exposure to electrophiles or reactive oxygen species, KEAP1
undergoes conformational changes that impair its substrate
adaptor function, leading to the accumulation of newly synthe-
sised NRF2, which can then translocates to the nucleus and
activates its target genes.32 Furthermore, NRF2 controls the
expression of a number of its own regulators (for example, KEAP1,
p66, p62), thus creating autoregulatory loops that control the
amplitude/duration of its own response.33–35
Although NRF2 is cytoprotective and its transient activation is
linked with chemoprevention,36 it has become apparent that its
sustained activation protects tumour cells against chemo- and
radiotherapy and can promote metabolic activities that support
cell proliferation and tumour growth.37–40 Not surprisingly, there-
fore, NRF2 is often constitutively activated in human tumours,39,41
where it is associated with poor prognosis.42–44 This sustained
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activation of NRF2 is especially relevant in lung tumours, where
due to mutations in KEAP1 or NFE2L2, NRF2 is constitutively
activated in 30–60% of cases.41,45 Additionally, NRF2 can be
upregulated by the oncogenic mutant KRAS, BRAF and Myc and
by loss of PTEN,46,47 suggesting that aberrant activation of NRF2 is
a common event in many cancer types.
In this study, we describe for the ﬁrst time the existence of
crosstalk between HIPK2 and NRF2 in which NRF2 regulates HIPK2
expression, and in turn, HIPK2 positively shapes the NRF2
response.
RESULTS AND DISCUSSION
NRF2 transcriptionally regulates basal and inducible levels of
HIPK2
Previously, we and others have shown that HIPK2 can affect redox
balance and might regulate oxidative stress responses.10,48,49
As NRF2 is arguably the main transcription factor associated with
oxidative stress responses, we wanted to test whether there was a
link between NRF2 and HIPK2. To do so, we ﬁrst used A549 cells
(lung cancer cells that possess constitutively active NRF2 due to
inactivating mutations on KEAP150). We found that NRF2 knockout
cells (NRF2-KO) have reduced protein and messenger RNA (mRNA)
basal levels of HIPK2; conversely, NRF2 reconstitution restored
both the protein and the mRNA levels of HIPK2 (Figure 1a). To
monitor NRF2 activity, we used the prototypic NRF2 target gene
NQO1 (Figure 1a; Supplementary Figure S1A). To our knowledge,
there are no studies to date addressing the transcriptional
regulation of HIPK2. We therefore conﬁrmed the effect of NRF2
on HIPK2 mRNA levels, ﬁrst by using different NRF2-KO cell lines
(Supplementary Figures S1B and S1C) and second, by using
various short hairpin RNA (shRNAs) against NRF2 (Supplementary
Figure S1D). These results demonstrate that NRF2 regulates the
steady-state levels of HIPK2.
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In order to answer whether NRF2 activation is also able to
induce HIPK2, we used two different approaches. In a pharmaco-
logical approach, we used two classical NRF2 activators, hydrogen
peroxide (H2O2) and sulforaphane (SFN), which disrupt the KEAP1-
dependent NRF2 degradation. We found that NRF2 activators
increase both mRNA and protein levels of HIPK2 in H1299 cells
(lung cancer cells with functional KEAP1), and that this induction
requires NRF2 (Figure 1b). Of note, other KEAP1-proﬁcient cell
lines showed similar behaviour (Supplementary Figure S1E), and
an overexpressed ﬂag-tagged HIPK2 construct does not get
stabilised by neither of NRF2 activators (Supplementary Figure
S1F). Additionally, we used a genetic model: by deleting the
KEAP1-binding motif within the endogenous NRF2, we produced
cells that harbour a constitutively active NRF2 gain-of-function
(GOF) mutant. Such GOF mutations are often found in tumours,
and have been associated with malignancy.43,44,51 Thus, NRF2-GOF
cells provide a physiologically relevant model of sustained NRF2
activation in malignant cells. We found that H1299 NRF2-GOF cells
have elevated protein and mRNA levels of HIPK2 and NQO1 when
compared with their WT counterparts (Figure 1c; Supplementary
Figure S1G). The upregulation of HIPK2 observed in NRF2-GOF
cells is not cancer cell type-speciﬁc (Supplementary Figure 1H).
This model demonstrates that sustained NRF2 activation increases
HIPK2 expression.
To identify the region(s) in the HIPK2 gene that is responsible for
its regulation by NRF2, we performed an in silico analysis of the
HIPK2 promoter to identify potential AREs that might be bound by
NRF2. The minimal proposed consensus ARE sequence is
TGASnnnGC (where S = C or G).52 As active AREs are often located
close to the transcription start site, we focused on two ARE
sequences we identiﬁed between − 1 and − 2000 bp within the
HIPK2 promoter, referred as ARE1 (at − 246 bp: 5ʹ-TGAGAGGGC-3ʹ)
and ARE2 (at − 1794 bp: 5ʹ-TGACTTAGC-3ʹ). Additionally, Malhotra
et al.52 using ChIP-seq in mouse cells, detected 1256 peaks as
potential NRF2 binding sites. Among these, we identiﬁed a peak
within a HIPK2 intronic region; as this ARE sequence is conserved
in humans (named intronic ARE: 5ʹ-gTGACTCAGCg-3ʹ), we
analysed all three potential sites by studying NRF2 occupancy
via ChIP-qPCR analyses. We used DLD1 cells to immunoprecipitate
endogenous NRF2 and to interrogate its ability to bind to the
three potential AREs. The analysis was performed by comparing
the amount of material immunoprecipitated with anti-NRF2
Figure 1. HIPK2 is a novel NRF2 target gene. (a) All cell lines used in the study have been validated by STR proﬁling and were routinely tested
for mycoplasma. When applicable, the differences between groups were determined by unpaired Student’s t-test. Analyses were performed
using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA); a P-value of o0.05 was considered signiﬁcant. *P⩽ 0.05, **P⩽ 0.01,
***P⩽ 0.001. The endogenous NFE2L2 gene, which encodes NRF2, was edited by transfecting cells with pLentiCRISPR-v2 (a gift from Dr Feng
Zhang, Addgene plasmid #52961) containing a guide RNA (gRNA) directed against the KEAP1-binding domain within the NFE2L2 locus
(5ʹ-TGGAGGCAAGATATAGATCT-3ʹ). CRISPR-mediated gene editing with this gRNA produced NRF2 knockout clones (NRF2-KO), and NRF2 gain-
of-function clones (NRF2-GOF). NRF2-GOF clones were those that the Cas9-mediated cleavage was repaired in frame but introducing
mutations (deletions or insertions) within the KEAP1-binding domain. After 2 days of puromycin selection, cells were clonally selected by serial
dilution, and positive clones were identiﬁed as previously described.66 Control cells (referred as wild-type) comprises the pooled population of
surviving cells transfected with pLentiCRISPRv2 vector (empty backbone) treated with puromycin. Mutational gene changes in NFE2L2 were
validated by sequencing of their genomic DNA. All our results were validated using at least two different clones from each gRNA. Lentiviral
infections were performed as previously described.10 Left panel: A549 cells were grown in DMEM (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) containing 10% fetal bovine serum (FBS). A549 control cells (WT) infected with empty vector were compared with CRISPR-mediated
NRF2 knockout cells (NRF2-KO) infected with empty vector or with lentivirus encoding NRF2 (NRF2 Rec). Protein levels of human NRF2
(ab62352, Abcam, Cambridge, UK), HIPK26 and NQO167 were analysed by western blotting. Tubulin was used as a loading control (TU-02,
Santa Cruz Biotechnology, Dallas, TX, USA). Note that antibodies against human NRF2 recognise a non-speciﬁc protein as a faster migrating
band; such band has been previously described.68–70 The asterisk marks the position of the non-speciﬁc band. Right panel: TaqMan analyses of
HIPK2 mRNA levels in A549 control cell lines (WT) compared with NRF2-KO cells or NRF2-KO cells reconstituted with NRF2 (NRF2 Rec). The
data were normalised using β-actin as an internal control. The mRNA levels in WT cells were set as 1. Values are means plus s.d. from three
independent experiments. RNA was extracted using RNeasy kit (Qiagen, Hilden, Germany), and reverse-transcribed to complimentary DNA
(cDNA) using Omniscript RT kit (Qiagen) according to the manufacturer’s instructions. Resulting cDNA was analysed using TaqMan Universal
Master Mix II (Life Technologies, Carlsbad, CA, USA). Gene expression was determined using an Applied Biosystems (Foster City, CA, USA) 7300
Real-Time PCR system by the comparative ΔΔCT method. The following primers and probes were used in the study: hHIPK2-F
5ʹ-CATGAAGCAGAGACAGGGAT-3ʹ, hHIPK2-R 5ʹ-CATCAATGGTCAGCATCTTC-3ʹ, hHIPK2-Probe 5ʹ-GATGATATGGCCCAGGTGA-3ʹ, hActin-F
5ʹ-GCGCGGCTACAGCTTCA-3ʹ, hActin-R 5ʹ-TCTCCTTAATGTCACGCACGAT-3ʹ, hActin-Probe 5ʹ-CACCACGGCCGAGCGGGA-3ʹ. (b) WT or NRF2-KO
H1299 were treated with vehicle, 100 μM hydrogen peroxide (H2O2) or with 3 μM Sulforaphane (SFN). After 3 h, cells were lysed and subjected
to western blotting or mRNA analyses (RT-qPCR). Upper panel: levels of HIPK2 mRNA were analysed. The mRNA levels in vehicle-treated
WT cells were set as 1. Values are means plus s.d. from ﬁve independent experiments. Sulforaphane [1-isothiocyanato-4(R,S)-(methylsulﬁnyl)
butane] was obtained from LKT Labs (St. Paul, MN, USA). Lower panel: the levels of the indicated proteins were analysed. HO1 antibody was
purchased from Biovision (Biovision Inc., Milpitas CA, USA). (c) H1299 control cells (WT) were compared with CRISPR-mediated NRF2 gain-of-
function (NRF2-GOF) H1299 cells. Results obtained using two independent NRF2-GOF clones are shown. Left panel: the levels of the indicated
proteins were analysed. Right panel: Taqman analysis of HIPK2 mRNA levels. (d) ChIP analysis of NRF2 occupancy within the HIPK2 proximal
promoter (ARE1 and ARE2), HIPK2 intronic region (Intron) and the previously characterised ARE within the NQO1 promoter.71 ChIp analyses
were performed as previously described71 using the following primers: NQO1-ARE-F 5ʹ-CCCTTTTAGCCTTGGCACGAAA-3ʹ, NQO1-ARE-R
5ʹ-TGCACCCAGGGAAGTGTGTTGTAT-3ʹ, HIPK2-ARE-Intron-F 5ʹ-GTCCCATTATACCTTCGCAG-3ʹ, HIPK2-ARE-Intron-R 5ʹ-AGCATGTCCACAGAGC
CTC-3ʹ, HIPK2-ARE1-F 5ʹ-GCGTGCACACACACACACAAAG-3ʹ, HIPK2-ARE1-R 5ʹ-GGAAGGCCGAACCGAAGGG-3ʹ, HIPK2-ARE2-F 5ʹ-ACAGTGACAGAG
ATGGGTGAAG-3ʹ, HIPK2-ARE2-R 5ʹ-GTGCCTTGGCTTTTCATCAAGG-3ʹ. Left panel: the amount of material immunoprecipitated with anti-NRF2
(ab62352, Abcam) in DLD1 (WT) versus DLD1 NRF2-KO cells was compared. Right panel: we compared the amount of material
immunoprecipitated with anti-NRF2 in DLD1 (WT) versus DLD1 NRF2-GOF cells. All data were normalised against the input lysates before
enrichment by immunoprecipitation. Values are means plus s.d. from three independent experiments. (e) Luciferase gene reporter assay to
identify functional AREs within the HIPK2 locus. The proximal HIPK2 promoter (−1 to − 2000) and the HIPK2 intronic region (a 700 bp region
spanning the identiﬁed ARE) were cloned into the basic-pGL3-luc vector, upstream and downstream of the luciferase gene, respectively. We
used Nqo1-luc and mutARE-Nqo1-Luc as positive and negative controls, respectively.56 The indicated constructs were transfected into RL-34
cells (grown in DMEM containing 10% FBS) using Lipofectamine 2000. About 24 h after transfection, cells were treated either with vehicle or
with 50 nM of TBE-31.54 Sixteen hours later, cells were lysed and their luciferase expression analysed using the Luciferase Assay System from
Promega (Madison, WI, USA). The luciferase levels in vehicle-treated cells were set as 1. Values are means plus s.d. from ﬁve independent
experiments.
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antibodies in WT and NRF2-KO DLD1 cells (Figure 1d, left panel).
Additionally, we compared the amount of material immunopre-
cipitated with anti-NRF2 or anti-IgG in DLD1 cells (Supplementary
Figure S1I). Our results showed that at basal conditions NRF2
binds to the ARE1 and to the intronic ARE, but not to the more
distal ARE2 sequence. Furthermore, we tested whether activation
of NRF2 leads to an increase in its binding to the HIPK2 locus. To
do so, we used NRF2-GOF DLD1 cells as a model for NRF2-
sustained activation and we compared them with DLD1 WT cells,
and found that NRF2 activation leads to an enrichment of NRF2
bound to the HIPK2 locus (Figure 1d, right panel). Finally, to
address the potential functional relevance of the two identiﬁed
sites, we used a luciferase-based genetic reporter assay. We
cloned the proximal promoter of HIPK2 and the ARE-containing
intronic region of HIPK2 upstream and downstream of
the luciferase gene, respectively, and individually mutated the
promoter ARE1 sequence and the intronic ARE sequence. We
transfected these constructs into RL-34 cells (which are highly
responsive to NRF2 inducers53) and tested their response to the
NRF2 inducer TBE-3154,55 (Figure 1e). We used plasmids containing
either the promoter of NQO1 fused to luciferase (WT) or the
promoter of NQO1 with a mutated ARE sequence fused to
luciferase (MUT)56 as a positive and a negative control, respec-
tively. Our results showed that while the ARE1 sequence situated
within the HIPK2 promoter does not control luciferase expression,
the ARE sequence within the intronic region of HIPK2 is
responsible for the TBE-31-mediated induction of luciferase,
highlighting the functional relevance of this ARE sequence.
Together, these results show that NRF2 regulates both basal
and inducible levels of HIPK2 at the transcriptional level via an
intronic ARE sequence. The identiﬁcation of a functional intronic
ARE, although rare, has been recently reported for another NRF2
target gene.57 To our knowledge, this is the ﬁrst demonstration of
a transcriptional mode of regulation for HIPK2.
HIPK2 supports NRF2 antioxidant response
Having demonstrated that HIPK2 is regulated by NRF2, we then
studied whether HIPK2 affects NRF2-dependent responses. First,
we found that HIPK2 overexpression promoted the accumulation
of a nuclear, lambda phosphatase-sensitive form of NRF2 (in both
endogenous and overexpressed NRF2) (Figure 2a; Supplementary
Figure S2A). These results suggest that HIPK2 can activate NRF2 by
promoting its nuclear accumulation, in a similar way as exposure
to the oxidant H2O2 does (Supplementary Figure S2B). To test this
possibility, we compared wild-type (WT) and HIPK2 knockout MEF
cells and found that HIPK2-deﬁcient cells had lower basal protein
levels of NRF2 and the NRF2 target NQO1 and GSTM1 (Figure 2b),
as well as an impaired induction of NQO1 after SFN treatment, as
measured by enzyme activity (Figure 2c). Furthermore, HIPK2
reconstitution rescued (i) the basal mRNA levels of NRF2 target
genes (Figure 2d) and their induction (in response to oxidants)
(Supplementary Figure 2C) without affecting the mRNA levels of
HIPK2 promotes cytoprotection via NRF2
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NRF2 itself, and (ii) the basal NRF2 protein levels, and its response
to oxidants (measured by induction of NQO1 and HO1 levels upon
exposure to H2O2) (Figure 2e). In these experiments, we used
HIPK1/2-double knockout MEF cells to avoid potential compensa-
tion from HIPK1;2,3,58 similar results were obtained in single HIPK2
knockout cells (Supplementary Figure S2D). Interestingly, the
effect of HIPK2 on NRF2 is kinase dependent, as a HIPK2 kinase-
deﬁcient mutant form (KD) did not rescue the basal NRF2 levels or
the NRF2-mediated response (Figure 2e). However, based on our
results we cannot distinguish between the effect of HIPK2 on
NRF2 being direct or indirect.
To test the relevance of HIPK2 in the regulation of NRF2 in
human cancer cells, we produced CRISPR-mediated HIPK2 knock-
out cells. We found that HIPK2 knockout decreased NRF2 levels in
both H1299 and A549 lung cancer cells (Figure 2f). These results
were conﬁrmed in various cell lines using shRNAs against HIPK2
(Supplementary Figures S2E and S2F).
To test whether HIPK2 regulates NRF2 response in vivo, we
analysed Hipk2, Nqo1 and Nrf2 mRNA levels from livers of wild-
type and HIPK2 knockout mice treated with a single dose of the
NRF2 inducer TBE-31. Compared to wild-type mice, HIPK2-
deﬁcient mice exhibited impaired induction of Nqo1 by TBE-31
(Figure 2g), without signiﬁcantly affecting Nrf2 mRNA levels
(Supplementary Figure S2G).
These results establish that HIPK2 contributes substantially to
the NRF2-mediated responses both in cells and in vivo. Moreover,
they highlight the potential role HIPK2 may play in ensuring a
robust adaptive response against oxidative stress and xenobiotics.
Of note, this new link between HIPK2 and oxidative stress
responses is conserved throughout evolution, as a recent
study demonstrated that in Caenorhabditis elegans, HPK-1 (the
single homologue of HIPKs), confers resistance to oxidative
stress.59
Physiological relevance of the crosstalk between HIPK2 and NRF2
NRF2 is well-characterised as being cytoprotective in healthy
tissue. In clear contrast, NRF2 increases resistance against a wide
variety of chemotherapeutic drugs in malignant tissue. The fact
that HIPK2 positively regulates NRF2 suggests that this HIPK2/
NRF2 axis could represent a new pathway by which HIPK2
prevents tumour initiation. However, the existence of such axis
provides a means by which HIPK2 might, via NRF2, play a hitherto
unrecognised role in mediating survival of malignant cells upon
challenge with chemotherapeutic drugs.
To address whether HIPK2 affects cell responses to chemother-
apeutic drugs via NRF2, we used two different approaches. First,
we reconstituted HIPK1/2-KO cells with HIPK2 (or with an empty
vector) and exposed both isogenic cell lines to increasing
concentrations of the commonly used chemotherapeutic drug
doxorubicin. We found that, compared to HIPK1/2-KO MEFs, cells
reconstituted with HIPK2 exhibited higher cell viability (Figure 3a)
and a striking reduction of apoptosis (measured by PARP
cleavage) in response to doxorubicin, correlating with higher
levels of NRF2 and NQO1 (Figure 3b). In full agreement with the
apoptosis data, HIPK2-reconstituted cells were more resistant to
doxorubicin (measured by cell viability), and this resistance was
signiﬁcantly reduced by NRF2 knockdown (Figure 3c). Second, we
Figure 2. HIPK2 controls the NRF2 levels and shapes the NRF2 response. (a) H1299 cells were transfected using Lipofectamine 2000 with
increasing concentrations of HA-tagged HIPK2.10 Cells were lysed 48 h after transfection and nuclear and cytosolic fractions were separated as
previously described.72 Half of the protein extract was treated with Lambda phosphatase (New England Biolabs, Ipswich, MA, USA) for 1 h at
37 °C, boiled and analysed by western blotting using the indicated antibodies. Anti-HA (Y-11) was purchased from Santa Cruz Biotechnology.
HDAC1 (H-51, Santa Cruz Biotechnology) and tubulin were used as markers for the nuclear and cytosolic fractions, respectively. The asterisk
marks the position of an unspeciﬁc band. An empty gel lane was left between loading of the cytosolic and nuclear fractions. (b) WT or
HIPK1/2-KO MEF cells2 (obtained from Dr Issay Kitabayashi (National Cancer Center Research Institute, Tokyo, Japan) grown in DMEM
containing 10% fetal bovine serum (FBS) and 1% (w/v) penicillin/streptomycin were analysed by western blot for the levels of the indicated
proteins using antibodies against HIPK2, NRF2,31 NQO1, GSTM131,67 and Tubulin. (c) WT or HIPK1/2-KO MEF cells were treated with vehicle (V)
or with 3 μM Sulforaphane (SFN). After 7 h, cells were lysed and the speciﬁc activity of NQO1 was analysed as previously described.73 Values are
means plus s.d. from three independent experiments. (d) Isogenic HIPK1/2-KO cells infected with empty vector or lentivirally reconstituted
with HIPK2 (HIPK2 Rec) as described10 were analysed for the mRNA levels of Hipk2, Nrf2 and NRF2 target genes. The data were normalised
using β-actin as an internal control. The mRNA levels of HIPK1/2-KO cells were set as 1. Values are means plus s.d. from three independent
experiments. TaqMan probes were produced (mGstm1-Fw-primer 5'-CAAACCTGAGGGACTTCCTG-3', mGstm1-Rev-primer
5'-ATAGGTGTTGCGATGTAGCG-3', mGstm1-Probe 5'-CCGCTTCGAGGGCCTCAAGA-3') or obtained from Applied Biosystems: mNqo1
(Mm01253561_m1), mHipk2 (Mm00439329_m1), mActin (Mm00607939_s1), mHo1 (Mm00516005_m1), mGclc (Mm00802655_m1) and mNrf2
(Mm00477784_m1). (e) HIPK1/2-KO MEF were infected with empty vector (Control), or with virus encoding HIPK2 wild-type (HIPK2-WT Rec) or
a kinase defective form of HIPK2 (HIPK2-KD Rec) as previously described.10 After puromycin selection, the isogenic cell lines were treated with
increasing concentrations of hydrogen peroxide (20, 50, 75 μM). Eight hours later, cells were lysed and analysed for levels of the indicated
proteins. (f) The endogenous HIPK2 gene was knockedout by transfecting cells with pLentiCRISPR-v2 containing a guide RNA (gRNA) against
the second exon of HIPK2 (5'-GCGAGGGCGACTATCAGC-3'). An additional gRNA (5'-GTGGTTCTTCAGGATCTTGA-3') was used to validate the
results (data not shown). Control cells (referred as WT cells) were transfected with the empty pLentiCRISPRV2 vector. After 2 days of puromycin
selection, cells were clonally selected by serial dilution, and positive clones were identiﬁed as previously described.66 Mutational gene
changes in HIPK2 were validated by sequencing of their genomic DNA. H1299 and A549 cells (WT) were compared with CRISPR-mediated
H1299 and A549 HIPK2-KO cells. Protein levels of NRF2 and HIPK2 were analysed. Results obtained with two independent clones are shown.
The asterisk marks the position of a non-speciﬁc band. (g) Hipk2+/− mice crossed onto a C57BL/6 background (eight generations of
backcrossing) were used.3 The heterozygous mice were intercrossed and their offspring, wild-type (WT) and Hipk2− /− (HIPK2-KO), both male
and female, were used for experiments at 8 weeks of age. Control mice (WT) or HIPK2 knockout mice (HIPK2-KO) were treated with the NRF2
inducer TBE-31: stock solution (3 mM) of TBE-31 was initially prepared in DMSO, and then diluted in phosphate-buffered saline at a 1:3 (v/v)
ratio. The animals received TBE-31 (100 nmol/20 g body weight, 100 μl, i.p.) or the equivalent (100 μl) volume of vehicle (DMSO, 100 nmol/20 g
body weight). After 16 h, livers were extracted and snap-frozen in liquid nitrogen. Samples were sectioned in ⩽ 30 mg fragments. RNA was
extracted using RNeasy kit (Qiagen). Tissue was disrupted adding the appropriate volume of lysis buffer containing β-mercaptoethanol
according to the manufacturer’s instructions and homogenised. Levels of Hipk2 and Nqo1 mRNA were evaluated. The data were normalised
using β-actin as an internal control. The mRNA levels of one of the WT control mouse were set as 1. Values are means plus s.d. n= 3 mice per
group. The sample size was calculated using G*Power software v3.174 to ensure P= 0.05 at 95% power between treated samples in both
genotypes. The differences between groups were determined by unpaired Student’s t-test. All animal experiments were carried out according
to the in-house guidelines for the care and use of laboratory animals of the RIKEN, Yokohama Institute, Japan. Mice were assigned a random
number, and treatments were blinded from the operator performing the data analysis.
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knockedout HIPK2, NRF2 or both genes in H1299 lung cancer cells,
and measured their sensitivity to cisplatin compared with wild-
type cells. HIPK2 knockout (or knockdown) increased the
sensitivity to cisplatin as seen by a colony-formation assay
(Figure 3d). Furthermore, whereas knockout of NRF2 sensitised
cells to cisplatin, a double knockout of both NRF2 and HIPK2 did
not increase drug sensitivity further as shown by a cell viability
assay (Figure 3e).
Figure 3. HIPK2 promotes cytoprotection via NRF2. (a) HIPK1/2-KO MEFs reconstituted with empty vector (Control) or with HIPK2 (HIPK2 Rec)
were exposed to increasing concentrations (0.01, 0.05, 0.1, 0.5, 1 μg/ml) of Doxorubicin (Doxo) (Sigma-Aldrich, St Louis, MO, USA) for 4 h. After
removal of the medium, the cells were washed and those that survived were further grown in complete DMEM. After 3 days, cells were
washed with phosphate-buffered saline and ﬁxed with ice-cold methanol for 10 min, stained with a crystal violet solution (0.5% crystal violet,
25% ethanol) for 20 min and rinsed with water to remove the excess of dye. (b) HIPK1/2-KO reconstituted with empty vector (Control) or with
HIPK2 (HIPK2 Rec) were exposed to increasing concentrations (0.01, 0.05, 0.1, 0.5, 1 μg/ml) of Doxo. After 12 h, cells were analysed for the
levels of the indicated proteins by western blot. Antibodies against cleaved PARP (cl.PARP, #9544) were obtained from Cell Signalling (Danvers,
MA, USA). In the gels there is an empty lane between both cell lines. (c) HIPK1/2-KO MEF and HIPK1/2-KO MEF reconstituted with HIPK2 were
infected with virus carrying a non-targeting shRNA (shControl; SIGMA Mission shRNA PLKO.1-puro) or an shRNA against NRF2 (SIGMA Mission
shRNA. TRCN0000007555, targets 5'-AAAAGCTCCTACTGTGATGTGAAAT-3'). Equal number of cells were seeded in a 96-well plate and treated
with doxorubicin (0.5, 1 μg/ml) for 4 h. After removal of the medium, cells were washed once and those that survived were further grown in
complete DMEM for 3 days. At that point Alamar Blue was added to the media and incubated for 1–3 h at 37 °C according to the
manufacturer’s instructions. The resulting ﬂuorescence was quantiﬁed using a plate reader. Values are means+s.d. from three independent
experiments. Similar results were obtained using additional shNRF2 (SIGMA Mission shRNA. TRCN0000054658, targets 5'-
CCAAAGCTAGTATAGCAATAA-3') (Data not shown). (d) H1299- (WT) or CRISPR-mediated H1299 HIPK2-KO cells (upper panels), or H1299
infected with virus carrying a non-targeting shRNA (shControl) or an shRNA against HIPK2 (shHIPK2) (SIGMA Mission shRNA, TRCN0000023014,
targets 5'-CACCCATGATTCAGAATAAT-3') (lower panels) were exposed to increasing concentrations of cisplatin (2, 4, 8, 16, 20 μg/ml) for 12 h
followed by a medium exchange. The surviving cells were further grown for 3 days and stained with crystal violet. (e) H1299- (WT), CRISPR-
mediated H1299 HIPK2-KO, NRF2-KO or double NRF2/HIPK2-KO cells were seeded in 96-well plates and exposed to increasing concentrations
of cisplatin (2, 4, 8,16 μg/ml) for 8 h followed by a medium exchange. The surviving cells were further grown for 3 days and Alamar Blue was
added to the media. Cell viability was determined following absorbance measurement. Values are means plus s.d. from four independent
experiments.
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These results conﬁrm that HIPK2 can promote cell survival upon
challenge with chemotherapeutic drugs; this, together with the
involvement of the well-established pro-survival factor NRF2
makes a strong case for the idea that, by activating NRF2, HIPK2
could support cancer cell survival.
CONCLUSIONS
Herein, we demonstrate for the ﬁrst time that HIPK2 is regulated at
the transcriptional level and that HIPK2 is an NRF2 target gene.
This is a notable ﬁnding because most HIPK2 regulatory
mechanisms described to date rely on posttranslational modiﬁca-
tions and thus, our results add an extra regulatory layer to the
control of HIPK2 activity. Additionally, our data place HIPK2 as a
critical kinase, shaping the NRF2 response. This is important in the
cancer biology ﬁeld for two reasons: First, our discovery reveals
HIPK2 to be a common apical regulator of two major stress
regulated pathways, NRF2 and p53, and thus a decisive factor
controlling cancer cell fate by being coupled to both cell death
and cell survival. It is important to highlight that although HIPK2
can protect healthy tissue against tumour initiation by promoting
both DNA repair17,22 and cytoprotection (shown in this study),
activation of the same pro-survival pathways in malignant tissue
could lead to aberrant cell survival and enhanced chemoresis-
tance (see model in Figure 4), particularly when apoptotic
pathways are impaired (that is, in the absence of a functional
p53). In this context, it will be important in the future to address
whether HIPK2 plays opposing roles depending on the stages of
tumour development (for example, preventing initiation but
accelerating progression) as has also been proposed for NRF2.60
Interestingly, HIPK2 also controls the levels of Notch1,61 a well-
known factor with a dual role in cancer, which in common with
NRF2, can act as both tumour suppressor and oncogene,
depending on the context,62–65 adding strength to the idea of a
context-dependent role for HIPK2 in cancer. Second, our data
suggest that inhibition of HIPK2 could be a plausible mechanism
by which the NRF2 pathway could be suppressed, thereby
providing a new strategy to overcome NRF2-associated resistance
to therapies in malignant cells. It is recognised that aberrant-
sustained activation of NRF2 can promote chemoresistance and
radioresistance, and therefore, inhibition of NRF2 in these settings
should increase the efﬁcacy of anticancer therapies.
In summary, our results provide new information supporting the
already well-established tumour suppressor role of HIPK2, and also
could explain how under certain conditions (for example, cancer
cell chemoresistance due to upregulated NRF2) HIPK2 might
provide cancer cells with a survival advantage.
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